<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00902122</url>
  </required_header>
  <id_info>
    <org_study_id>rAd-p53-003</org_study_id>
    <nct_id>NCT00902122</nct_id>
  </id_info>
  <brief_title>rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors</brief_title>
  <official_title>Open-Label, Multi-Center, Randomized, Active-Controlled, Phase 4 Study of rAd-p53 Gene Mono-Therapy, With Concurrent Radioactive Iodine , or Combination With Surgery in Subjects With Advanced Malignant Thyroid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen SiBiono GeneTech Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen SiBiono GeneTech Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is multicenter, open-label, randomized, active-controled, phase IV study of local direct
      intra-tumor injection of rAd-p53 monotherapy, with concurrent radioactive iodine , or
      combination with surgery for treatment of advanced malignant thyroid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objectives of this study is to determine the efficacy profiles of rAd-p53 intra-tumor
      injection alone, with with concurrent radioactive iodine, or combination with surgery for
      treatment of advanced malignant thyroid tumors(stage III or IV) including target lesion
      complete response rate (LCR) and overall target lesion response rate (OLR), response duration
      (RD), and progress-free survival (PFS).

      The secondary objectives of this study is to investigate overall response rate (OPCR) and
      overall complete response rate (OCR), overall survival (OS), ECOG, and safety of rAd-p53
      monotherapy and combined with radioactive iodine,or surgery.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">August 2012</completion_date>
  <primary_completion_date type="Anticipated">August 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progress-free survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Advanced Malignant Thyroid Tumors</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Five times of p53 gene intratumoral injection are given before surgery,then radical surgery will be conducted.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>p53 gene therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>p53 gene therapy plus radioactive iodine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rAd-p53 gene</intervention_name>
    <description>pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 5 times</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgery</intervention_name>
    <description>removal of thyroid tumor</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>p53 gene therapy</intervention_name>
    <description>p53 gene treatment: 10exp12 virus particles per 3 days for 10 times</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>p53 gene therapy with radioactive iodine</intervention_name>
    <description>p53 gene therapy with concurrent radioactive iodine pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 10 times</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Advanced stages of thyroid malignant tumors (stage III and VI)

          2. At least one target tumor can be injected with study drug, the largest diameter
             greater than 2 cm

          3. Histologically confirmed Oral and Maxillofacial malignant tumors

          4. No prior chemotherapy, radiotherapy or biological tumor therapy in 2 weeks

          5. Age: 18-85 years old

          6. Expected to survive more 12 weeks

          7. ECOG:0-2

          8. Neutrophils≥1.5×109/L,Platelet≥ 80×109/L, Hb≥80g/L, bilitubin≤2mg/dl,ALT and AST
             ≤2×institutional upper limit of normal, Cr ≤1.5×institutional upper limit of
             normal,coagulation tests (PTT and INR) within normal range

          9. Subject provided signed informed consent -

        Exclusion Criteria:

          1. Hypersensitive to study drug

          2. Tumor(s) locate very close to important blood vessels and nerves, which affect
             injection

          3. With a coagulation and bleeding disorder

          4. With uncontrolled, intercurrent illness including but limited to symptomatic
             neurological illness, symptomatic congestive heart failure, unstable angina pectoris,
             significant pulmonary disease or hypoxia, or psychiatric illness

          5. Local infection close to injection site or systemic infection

          6. Pregnant or lactating

          7. Principle investigator consider not suitable
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jingqiang Zhu, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department Of Thyroid and breast Surgery, West China hospital, Sichuan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>aiqi wang, MD</last_name>
    <phone>86-755-33065218</phone>
    <email>aiqi.wang@sibiono.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jingqiang Zhu, PhD, MD</last_name>
      <phone>86-28-81812477</phone>
      <email>zjq-wkys@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2009</study_first_submitted>
  <study_first_submitted_qc>May 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2009</study_first_posted>
  <last_update_submitted>April 6, 2012</last_update_submitted>
  <last_update_submitted_qc>April 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>p53 gene</keyword>
  <keyword>thyroid</keyword>
  <keyword>gene therapy</keyword>
  <keyword>malignant tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iodine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

